Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

AIDS

Volumn 23, Issue 4, 2009, Pages 534-538

  Correction Monini, Paolo ^a   Sgadari, Cecilia ^a   Grosso, Maria Gabriella ^a   Bellino, Stefania ^a   Di Biagio, Antonio ^b   Toschi, Elena ^a   Bacigalupo, Ilaria ^a   Sabbatucci, Michela ^a   Cencioni, Giulia ^a   Salvi, Emanuela ^a   Leone, Patrizia ^a   Ensoli, Barbara ^a   Barillari, G ^a   Moracci, G ^a   Carratelli, L ^c   Gatti, G ^b   Brambilla, L ^d   Brambati, M ^d   Ferrucci, S ^d   De Pita O ^e   Pilla, M A ^e   Di Carlo, A ^f   Giuliani, M ^f   Cottoni, F ^g   Cuccuru, M A ^g   Calvieri, S ^h   Clerico, R ^h   Potenza, C ^h   Tirelli, U ⁱ   Simonelli, C ⁱ   Martellotta, F ⁱ   Strumia, R ^j   Borghi, A ^j   Del Giacco, S ^k   Moi, L ^k   Piludu, G ^k   Sirianni, M C ^h   Campagna, M ^h   Sarmati, L ^l   Andreoni, M ^l   Bianchini, G ^m   Sheldon, J ⁿ   Milzer, J ^o   Schulz, T ^o   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Preventive Medicine Center   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^g UNIVERSITY OF SASSARI   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j S ANNA HOSPITAL   (Italy)

^k UNIVERSITY OF CAGLIARI   (Italy)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m Hospital 'Umberto I'   (Italy)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INDINAVIR; FIBROBLAST GROWTH FACTOR 2;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; ENDOTHELIUM CELL; ERYTHEMA; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOREACTIVITY; INFLAMMATION; KAPOSI SARCOMA; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PRURITUS; SERODIAGNOSIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; ANTIVIRAL THERAPY; CANCER RECURRENCE; CELL COUNT; CYTOKINE PRODUCTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PROTEIN BLOOD LEVEL; RASH; TREATMENT DURATION;

EID: 62349120388     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283262a8d     Document Type: Article

References (18)

1. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001; 81:161-200.
2. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, et al. Inflammatory cytokines synergize with the HIV-I Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 1999; 163:1929-1935.
3. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-680.
4. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest 1995; 95:1723-1734.
5. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 1995; 154:3582-3592.
6. Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 1997; 158:1887-1894.
7. Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998; 152:1433-1443.
8. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. J Clin Invest 1994; 94:1736-1746.
9. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4:861-875.
10. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-232.
11. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eurl Dermatol 2003; 13:83-86.
12. Krown SE, Testa MA, Huang). AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-3092.
13. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97:3658-3661.
14. Andreoni M, El-Sawaf G, Rezza G, Ensoli B, Nicastri E, Ventura L, et al. High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. J Natl Cancer Inst 1999; 91:465-469.
15. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 348:1133-1138.
16. Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologie, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107:2282-2290.
17. Touloumi G, Hatzakis A, Potouridou I, Milona I, Strarigos J, Katsambas A, et al. The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. Int J Cancer 1999; 82:817-821.
18. Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000; 34:1414-1418.